Millions of Americans with diabetes struggle with diabetic peripheral neuropathy, an often painful complication of the disease that usually starts in the feet and legs before moving up to the hands and arms.
Medicare Expands Coverage For Spinal Cord Stimulation To Treat Diabetic Peripheral Neuropathy
Nevro Executives Say Their Device Offers An Option For Patients With Pain
Medicare’s recent expansion of coverage for spinal cord stimulation therapy to treat diabetic peripheral neuropathy could mean relief for some 11 million Americans. Executives from Redwood City, CA device maker Nevro talked to Medtech Insight about the expansion and what it means for patients who use their technology.
More from Diabetic Care
• By
After switching production of coatings for its continuous glucose monitors in-house to improve supply, Dexcom ran afoul of US FDA for failing to submit a premarket notification. Firm says launch of 15-day sensor will not be delayed by the problems.
• By
People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.
• By
Even if manufacturing challenges don’t derail the 2025 launch plans, the regulatory setback introduces new challenges for Dexcom’s continuous glucose monitors at a time when competition from Abbott and Medtronic is intensifying.
• By
Abbott’s international sales could be a key driver as firm looks to partnerships with insulin pump companies.
More from Device Area
• By
Abbott presented late-breaking data at the 2025 American College of Cardiology conference demonstrating that TriClip transcatheter edge-to-edge repair offers prolonged patient benefits compared to medical treatment alone after two years, which were not evident at one year.
• By
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.
• By
The Visby Medical Women’s Sexual Health Test is the first over-the-counter test cleared by the US Food and Drug Administration to detect chlamydia, gonorrhea and trichomoniasis. It delivers results in about 30 minutes.